Plozalizumab,Abbexa,abx831354

Plozalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CCR2/CD192, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.